Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Hj, Bloemendal"'
Autor:
Judith Kroep, Sc, Linn, Boven E, Hj, Bloemendal, Baas J, Ia, Mandjes, van den Bosch J, Wm, Smit, de Graaf H, Cp, Schröder, Gj, Vermeulen, Wc, Hop, Jw, Nortier
Publikováno v:
Europe PubMed Central
Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2), has shown activity in combination with capecitabine in patients with HER2-positive advanced breast cancer progressive on standard treatment regimens. We presen
Autor:
van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, the Netherlands., Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Hoes LR; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., van der Wijngaart H; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., de Vos FYF; Department of Medical Oncology, Utrecht University Medical Center, Utrecht, the Netherlands., Grünberg K; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3937-3943.
Autor:
Heerma van Voss MR; Meander Medical Center, Department of Internal Medicine, Amersfoort, The Netherlands. m.r.heermavanvoss@amsterdamumc.nl.; Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands. m.r.heermavanvoss@amsterdamumc.nl., Notohardjo J; Meander Medical Center, Department of Internal Medicine, Amersfoort, The Netherlands.; Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands., van Dodewaard-de Jong J; Meander Medical Center, Department of Internal Medicine, Amersfoort, The Netherlands., Bloemendal HJ; Meander Medical Center, Department of Internal Medicine, Amersfoort, The Netherlands.; Department of Medical Oncology, Research Institute for Medical Innovation, Radboudumc, Nijmegen, The Netherlands., Ter Heine R; Department of Pharmacy, Research Institute for Medical Innovation, Radboudumc, Nijmegen, The Netherlands.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Sep; Vol. 94 (3), pp. 437-441. Date of Electronic Publication: 2024 Jun 29.
Autor:
Slootbeek PHJ; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Luna-Velez MV; Department of Urology, Radboud university medical center, Nijmegen, The Netherlands., Privé BM; Department of Nuclear Medicine, Radboud university medical center, Nijmegen, The Netherlands., van der Doelen MJ; Department of Urology, Radboud university medical center, Nijmegen, The Netherlands., Kloots ISH; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Pamidimarri Naga S; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Onstenk HE; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Nagarajah J; Department of Nuclear Medicine, Radboud university medical center, Nijmegen, The Netherlands.; Roentgeninstitut Duesseldorf, Duesseldorf, Germany., Westdorp H; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., van Oort IM; Department of Urology, Radboud university medical center, Nijmegen, The Netherlands., Kroeze LI; Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands., Schalken JA; Department of Urology, Radboud university medical center, Nijmegen, The Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Mehra N; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands.
Publikováno v:
Theranostics [Theranostics] 2024 Aug 01; Vol. 14 (12), pp. 4555-4569. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).
Autor:
Verkerk K; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands., van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Oncology, LUMC, Leiden, the Netherlands.; Head of Melanoma Clinic, CHUV, Lausanne, Switzerland., van der Veldt AAM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.; Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Aarts MJB; Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Jalving M; Department of Medical Oncology, University of Medical Center Groningen, Groningen, the Netherlands., Gietema JA; Department of Medical Oncology, University of Medical Center Groningen, Groningen, the Netherlands., Devriese LA; Department of Medical Oncology, Division Beeld & Oncologie, Utrecht University Medical Center, Utrecht, the Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Center, Location VUMC, Cancer Center Amsterdam, the Netherlands., Barjesteh van Waalwijk van Doorn-Khosrovani S; CZ Health Insurance, Tilburg, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Smit EF; Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Publikováno v:
The Lancet regional health. Europe [Lancet Reg Health Eur] 2024 Mar 05; Vol. 39, pp. 100875. Date of Electronic Publication: 2024 Mar 05 (Print Publication: 2024).
Autor:
Overbeek JK; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands. Electronic address: Joanneke.Overbeek@radboudumc.nl., Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Mohmaed Ali MI; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands., Ottevanger PB; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands., Bloemendal HJ; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Hamberg P; Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, South Holland, the Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, the Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, Utrecht, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands., Opdam FL; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands., Ter Heine R; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands., van Erp NP; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Nov; Vol. 194, pp. 113346. Date of Electronic Publication: 2023 Sep 19.
Autor:
Yildirim H; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. h.yildirim@amsterdamumc.nl.; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location University of Amsterdam, 4F De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands. h.yildirim@amsterdamumc.nl., Widdershoven CV; Department of Urology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands., Aarts MJ; Department of Medical Oncology, GROW-School for Oncology and Development Biology, Maastricht University Medical Centre+, Maastricht, the Netherlands., Bex A; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; The Royal Free London NHS Foundation Trust, London, UK.; UCL Division of Surgery and Interventional Science, London, UK., Bloemendal HJ; Department of Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Bochove-Overgaauw DM; Department of Urology, Gelre Hospitals, Apeldoorn/Zutphen, The Netherlands., Hamberg P; Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam/Schiedam, the Netherlands., Herbschleb KH; Department of Internal Medicine, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands., van der Hulle T; Department of Medical Oncology, LUMC, Leiden, the Netherlands., Lagerveld BW; Department of Urology, OLVG, Amsterdam, The Netherlands., van Oijen MG; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location University of Amsterdam, 4F De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands., Oosting SF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands., van der Veldt AA; Department of Medical Oncology, Department of Radiology & Nuclear Medicine, Erasmus Medical Center-Cancer Institute, Rotterdam, the Netherlands., Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Zeijdner EE; Dutch Oncology Research Platform, Utrecht, The Netherlands., Aben KK; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.; Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands., van den Hurk C; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands., Zondervan PJ; Department of Urology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands., Bins AD; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC location University of Amsterdam, 4F De Boelelaan 1117, Amsterdam, 1081 HV, The Netherlands.
Publikováno v:
BMC cancer [BMC Cancer] 2023 Jul 11; Vol. 23 (1), pp. 648. Date of Electronic Publication: 2023 Jul 11.
Autor:
Vrinzen CEJ; Scientific Institute for Quality of Healthcare, Radboud University Medical Centre, Nijmegen, The Netherlands., Bloemendal HJ; Department of Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Jeurissen PPT; Scientific Institute for Quality of Healthcare, Radboud University Medical Centre, Nijmegen, The Netherlands.
Publikováno v:
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2023 Jul-Dec; Vol. 23 (9), pp. 989-999. Date of Electronic Publication: 2023 Sep 01.
Autor:
Slootbeek PHJ; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands., Kloots ISH; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands., van Oort IM; Department of Urology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands., Kroeze LI; Department of Pathology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands., Schalken JA; Department of Urology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA Nijmegen, The Netherlands.
Publikováno v:
Cancers [Cancers (Basel)] 2023 May 18; Vol. 15 (10). Date of Electronic Publication: 2023 May 18.
A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer.
Autor:
Vrinzen CEJ; Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands.; Netherlands Comprehensive Cancer Center (IKNL), Utrecht, The Netherlands., Delfgou L; Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands., Stadhouders N; Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands., Hermens RPMG; Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands., Merkx MAW; Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands.; Netherlands Comprehensive Cancer Center (IKNL), Utrecht, The Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands., Jeurissen PPT; Scientific Institute for Quality of Healthcare, Radboudumc, Nijmegen, The Netherlands.
Publikováno v:
Cancer research [Cancer Res] 2023 Apr 04; Vol. 83 (7), pp. 1147-1157.